Attach affordability conditions to the rights for medicines and technologies that come from public research funding
Steps to make it happen
- Governments and public funds review the terms they set when they pay for research.
- Universities and companies that get research money must first submit a plan for getting their inventions to people.
- Contracts that let a company use an invention's rights must include a promise to keep the price affordable.
- For poor countries, the price is set close to what it cost to make the product.
- If a promise is broken, other makers are allowed to produce the invention too.
- Anyone can see which research got how much public money.
- Medicines and technologies made with everyone's money reach the people who need them as a matter of course.
Water so far 💧 0
The proposal in detail
This proposal covers inventions that come from research money given by governments, public foundations, international public funds and the like, when those inventions bear directly on people's lives and well-being, such as medicines, vaccines, diagnostic tools, and technologies related to climate or food. The universities, research institutions and companies that receive the money may keep the patents and other rights to their inventions, but any contract that lets a company turn those rights into a product must include several conditions. The first is to show a plan for price and supply that lets the people who need the product actually get it. The second is that, for low-income countries, the product must be delivered at a price close to the cost of making it, or makers in those countries must be allowed to use the rights cheaply. The third is to make public how much public money was used, and at which stage. How strict the conditions are depends on the share of public money in the whole development, and they are lighter when only a very small part came from public funds. Basic technologies that are only used as research tools, and technologies with national security reasons, can be treated differently. If the promises are not kept, the side that provided the research money is allowed to let other makers use the rights. Whether a price is affordable is judged by a committee of experts independent of the funding body, taking into account the income level of each region.
BenefitsResults of public money reach the people who need them
The biggest advantage of this system is that medicines and technologies made with everyone's money are more likely to reach the people who truly need them, not only those who can pay. For people in low-income countries in particular, it could change whether they can get a life-saving medicine at all. It also eases the sense of unfairness that comes from the people who supported the research being made to pay a high price again. Because it is made public how much public money went into which research, society has more material to discuss how prices are set, and trust in how public funds are used also grows. Researchers, too, can more easily feel that their work is useful somewhere in the world, and can more easily explain its value to society. Setting the conditions in advance reduces the need to negotiate in a hurry once a crisis hits, and it becomes a foundation for delivering products faster and more fairly in emergencies such as a major outbreak of an infectious disease.
DrawbacksIt may weaken the drive to create new medicines and technologies
What people who oppose this worry about most is that investment in development will shrink and new medicines and technologies will become harder to create at all. Even if the research starts with public money, the clinical trials and factory building needed to reach a product cost far more and carry a much larger risk of failure, and that burden is usually carried by private companies. If conditions are placed on prices, companies may avoid working with public research, or may give up on development altogether. That would cause a loss that is hard to see: patients who could have been saved in the future are not. It is also hard to decide what an affordable price actually is, and disputes over those judgments and the burden of the procedures would grow. Many pieces of research often each contribute a little to a single product, so it is not easy to measure exactly how much the public money contributed. If income from licensing rights falls, university research funds may shrink, and if the conditions differ from country to country, it may even cause more confusion.
Learn the background
Behind many new medicines and technologies, the research that started them was supported by public money such as taxes and donations. But once the results become products, the company that holds the rights sets the price, and it can be very high. As a result, people in the country that supported the research end up paying a high price a second time, or people in low-income countries cannot get the product at all. When an infectious disease spread around the world, vaccines and treatments gathered first in wealthy countries, and the large differences in who received them first became widely known. There is concern that something similar could happen with technologies for dealing with climate change. Meanwhile, there are still not many cases where the people who give research money also decide who will receive the results and how. When we think about how to fund research, it is not enough to decide what to study and whom to trust with it. We are also asked to follow where the results end up.
Choose them ready to accept their drawbacks too (up to 5)
It helps pay for the server and the AI's planting
This proposal was written in Japanese by AI (claude-opus-5-5, policy version 2026-10-15d) and translated by AI (claude-sonnet-5-5). Nobody has checked the facts. Read the original (日本語) How the AI writes